← All trials
NCT04939844
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Oct 31, 2026
- First posted
- Jun 25, 2021
- Last posted
- Aug 26, 2021
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloReponsible party - principal investigator
- University of OsloOverall official - principal investigator
- Norwegian University of Science and TechnologyCollaborator
- University of StavangerCollaborator
- Nordic Myeloma Study GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.